Answers are grounded in this paper and cite their sources.
B-cell maturation antigen (BCMA) is a promising target for immunotherapy in plasma cell dyscrasias, but no commercial BCMA-directed CAR T-cell product is approved in Europe for patients with systemic light chain (AL) amyloidosis. We used the in-house manufactured 2nd-generation BCMA-directed MDC-CAR-BCMA001 for the treatment of patients with relapsed/refractory (R/R) AL amyloidosis. This is the first experience with this new high-avidity, academic CAR T-cell product in this population. Seven patients received 800 × 10 6 CAR T-cells after lymphodepletion. Leukapheresis, manufacturing and administration of CAR T-cells were performed in-house. Six patients had triple-class refractory disease (5/7 (71%) with prior high-dose chemotherapy). Active disease was present in 6/7 (86%) patients prior to CAR T-cell infusion. Overall response was observed in 6/7 patients (ORR 86%, 3 MRD-negative complete remissions). All patients with durable hematologic responses showed organ responses (cardiac, renal, improvement in polyneuropathy and myopathy) with rapid suppression of amyloidogenic free light chains. Six patients (86%) are alive, and 3/6 responders remain in remission after a median follow-up of 10.9 months. All patients experienced cytokine release syndrome, 5/7 grade ≤ 2, two grade 3, resolving after tocilizumab and/or dexamethasone. One patient experienced low-grade late immune effector cell-associated hematotoxicity. No neurotoxicity was observed. MDC-CAR-BCMA001 demonstrates high efficacy with manageable toxicity, making it a promising treatment for AL amyloidosis patients with preexisting organ insufficiencies. Deep responses and MRD negativity enable meaningful organ responses. Further evaluation as second-line therapy is planned in the ongoing clinical trial designated CLEAR AL (EU CT No. 2025-520790-39-00).
No takes yet. Share an insight, caveat, or question.
Farid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: